Sanofi Considers Counteroffer to J&J's for Actelion

Dec 06, 2016

Bloomberg

According to a Bloomberg article, Sanofi is discussing a counteroffer for Actelion Ltd., which would challenge Johnson & Johnson's move to acquire the Swiss biotech company, sources said.

Sanofi has informally expressed interest in Actelion, but hasn’t made a final decision on whether to proceed with a bid, the story said.

J&J recently increased its original offer to acquire Actelion, causing potential counter bidders to move quickly.

Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments